Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 16

1.

Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.

Wilky BA, Loeb DM.

Clin Exp Pharmacol. 2013 Jun;3(3). pii: 1000131.

2.

Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.

Salem K, McCormick ML, Wendlandt E, Zhan F, Goel A.

Redox Biol. 2015;4:23-33. doi: 10.1016/j.redox.2014.11.002. Epub 2014 Nov 18.

3.

Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity.

Ando M, Hoyos V, Yagyu S, Tao W, Ramos CA, Dotti G, Brenner MK, Bouchier-Hayes L.

Cancer Gene Ther. 2014 Nov;21(11):472-82. doi: 10.1038/cgt.2014.53. Epub 2014 Oct 17.

4.

Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.

Yarde DN, Nace RA, Russell SJ.

Exp Hematol. 2013 Dec;41(12):1038-49. doi: 10.1016/j.exphem.2013.09.005. Epub 2013 Sep 22.

5.

Concurrent whole brain radiotherapy and bortezomib for brain metastasis.

Lao CD, Friedman J, Tsien CI, Normolle DP, Chapman C, Cao Y, Lee O, Schipper M, Van Poznak C, Hamstra D, Lawrence T, Hayman J, Redman BG.

Radiat Oncol. 2013 Aug 21;8:204. doi: 10.1186/1748-717X-8-204.

6.

Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.

Salem K, Brown CO, Schibler J, Goel A.

Exp Hematol. 2013 Feb;41(2):209-18. doi: 10.1016/j.exphem.2012.10.002. Epub 2012 Oct 11.

7.

Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase.

Brown CO, Salem K, Wagner BA, Bera S, Singh N, Tiwari A, Choudhury A, Buettner GR, Goel A.

Biochem J. 2012 Jun 15;444(3):515-27. doi: 10.1042/BJ20112019.

8.

Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.

Goel A, Spitz DR, Weiner GJ.

J Cell Biochem. 2012 Feb;113(2):419-25. doi: 10.1002/jcb.23387. Review.

9.

Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis.

Bera S, Greiner S, Choudhury A, Dispenzieri A, Spitz DR, Russell SJ, Goel A.

Neoplasia. 2010 Dec;12(12):980-92.

10.

Clinical development of novel proteasome inhibitors for cancer treatment.

Yang H, Zonder JA, Dou QP.

Expert Opin Investig Drugs. 2009 Jul;18(7):957-71. doi: 10.1517/13543780903002074. Review.

11.

The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.

Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker MD, Goeckeler WF, Schlom J, Hodge JW.

Clin Cancer Res. 2008 Jul 1;14(13):4241-9. doi: 10.1158/1078-0432.CCR-08-0335.

12.

Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation.

Kim K, Brush JM, Watson PA, Cacalano NA, Iwamoto KS, McBride WH.

Mol Cancer Res. 2008 Mar;6(3):426-34. doi: 10.1158/1541-7786.MCR-07-0313.

13.

Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.

Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD Jr, Barlogie B, van Rhee F.

Blood. 2008 Feb 1;111(3):1309-17. Epub 2007 Oct 18.

14.

Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.

Goel A, Carlson SK, Classic KL, Greiner S, Naik S, Power AT, Bell JC, Russell SJ.

Blood. 2007 Oct 1;110(7):2342-50. Epub 2007 May 21.

15.
16.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk